Changes
On July 13, 2023 at 8:04:10 PM UTC, Chimwemwe Mkandawire:
f | 1 | { | f | 1 | { |
2 | "author": "", | 2 | "author": "", | ||
3 | "author_email": "", | 3 | "author_email": "", | ||
4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | 4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | ||
n | 5 | "groups": [], | n | 5 | "groups": [ |
6 | { | ||||
7 | "description": "", | ||||
8 | "display_name": "Monitoring Tools", | ||||
9 | "id": "d0eb5469-759e-4ce6-9b27-4330b78dc900", | ||||
10 | "image_display_url": | ||||
11 | ealth.gov.mw/uploads/group/2022-03-17-123717.467925211661eyeicon.png", | ||||
12 | "name": "monitoring-tool", | ||||
13 | "title": "Monitoring Tools" | ||||
14 | } | ||||
15 | ], | ||||
6 | "id": "b29dd35e-fbfd-4f08-94ed-dfe0a222b911", | 16 | "id": "b29dd35e-fbfd-4f08-94ed-dfe0a222b911", | ||
7 | "isopen": false, | 17 | "isopen": false, | ||
8 | "license_id": "notspecified", | 18 | "license_id": "notspecified", | ||
9 | "license_title": "License not specified", | 19 | "license_title": "License not specified", | ||
10 | "maintainer": null, | 20 | "maintainer": null, | ||
11 | "maintainer_email": null, | 21 | "maintainer_email": null, | ||
12 | "metadata_created": "2023-07-13T19:57:26.642548", | 22 | "metadata_created": "2023-07-13T19:57:26.642548", | ||
n | 13 | "metadata_modified": "2023-07-13T20:00:28.503488", | n | 23 | "metadata_modified": "2023-07-13T20:04:10.336046", |
14 | "name": "hiv-drug-resistance-testing-application-form-version2", | 24 | "name": "hiv-drug-resistance-testing-application-form-version2", | ||
15 | "notes": "* This form is used for requesting the National HIV drug | 25 | "notes": "* This form is used for requesting the National HIV drug | ||
16 | resistance (HIVDR) Expert Committee Patients to review a patient with | 26 | resistance (HIVDR) Expert Committee Patients to review a patient with | ||
17 | confirmed viral failure for potential drug resistance testing. | 27 | confirmed viral failure for potential drug resistance testing. | ||
18 | Patients on DTG- and PI-based regimens who don\u2019t re-suppress | 28 | Patients on DTG- and PI-based regimens who don\u2019t re-suppress | ||
19 | below 1000 copies/ml after an initial high VL despite good adherence | 29 | below 1000 copies/ml after an initial high VL despite good adherence | ||
20 | need a genotype sample for resistance testing.\r\n* Contact the HIVDR | 30 | need a genotype sample for resistance testing.\r\n* Contact the HIVDR | ||
21 | Expert Committee, either through the Department of HIV, STI and Viral | 31 | Expert Committee, either through the Department of HIV, STI and Viral | ||
22 | Hepatitis, or by sending an email to | 32 | Hepatitis, or by sending an email to | ||
23 | 3rdlineart@lighthouse.org.mw.\r\n* Follow the instructions on the | 33 | 3rdlineart@lighthouse.org.mw.\r\n* Follow the instructions on the | ||
24 | application form and ensure that the application form is completely | 34 | application form and ensure that the application form is completely | ||
25 | filled before sending it to the expert committee.\r\n* The expert | 35 | filled before sending it to the expert committee.\r\n* The expert | ||
26 | committee will advise if a genotype sample needs to be collected. | 36 | committee will advise if a genotype sample needs to be collected. | ||
27 | Genotyping is only possible if the current VL is 1000+ and will be | 37 | Genotyping is only possible if the current VL is 1000+ and will be | ||
28 | more reliable from 5000+.\r\n* The genotype result can only be | 38 | more reliable from 5000+.\r\n* The genotype result can only be | ||
29 | interpreted correctly if the patient has been taking their ARVs | 39 | interpreted correctly if the patient has been taking their ARVs | ||
30 | consistently for 2-3 months before the sample was collected.\r\n* | 40 | consistently for 2-3 months before the sample was collected.\r\n* | ||
31 | Maintain the current regimen until genotyping results are | 41 | Maintain the current regimen until genotyping results are | ||
32 | available.\r\n* Follow the regimen recommendations from the National | 42 | available.\r\n* Follow the regimen recommendations from the National | ||
33 | HIVRDR expert committee.\r\n", | 43 | HIVRDR expert committee.\r\n", | ||
34 | "num_resources": 1, | 44 | "num_resources": 1, | ||
n | 35 | "num_tags": 4, | n | 45 | "num_tags": 5, |
36 | "organization": { | 46 | "organization": { | ||
37 | "approval_status": "approved", | 47 | "approval_status": "approved", | ||
38 | "created": "2021-10-14T11:02:35.234558", | 48 | "created": "2021-10-14T11:02:35.234558", | ||
39 | "description": "The Department of HIV & AIDS (DHA) was established | 49 | "description": "The Department of HIV & AIDS (DHA) was established | ||
40 | in 2001, initially as a unit in the Department of Clinical Services, | 50 | in 2001, initially as a unit in the Department of Clinical Services, | ||
41 | to coordinate the biomedical HIV Program in Malawi. The department now | 51 | to coordinate the biomedical HIV Program in Malawi. The department now | ||
42 | carries responsibility for various HIV related programs including: | 52 | carries responsibility for various HIV related programs including: | ||
43 | sexually transmitted infections (STIs), prevention of mother to child | 53 | sexually transmitted infections (STIs), prevention of mother to child | ||
44 | transmission of HIV (PMTCT), and national voluntary male medical | 54 | transmission of HIV (PMTCT), and national voluntary male medical | ||
45 | circumcision program (VMMC). All these HIV program sub-sections are | 55 | circumcision program (VMMC). All these HIV program sub-sections are | ||
46 | linked to one robust monitoring and evaluation sub-section in the HIV | 56 | linked to one robust monitoring and evaluation sub-section in the HIV | ||
47 | and AIDS Department which technically operates under the Central | 57 | and AIDS Department which technically operates under the Central | ||
48 | Monitoring and Evaluation Department (CMED) of the Ministry of | 58 | Monitoring and Evaluation Department (CMED) of the Ministry of | ||
49 | Health.", | 59 | Health.", | ||
50 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 60 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
51 | "image_url": | 61 | "image_url": | ||
52 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | 62 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | ||
53 | "is_organization": true, | 63 | "is_organization": true, | ||
54 | "name": "dha", | 64 | "name": "dha", | ||
55 | "state": "active", | 65 | "state": "active", | ||
56 | "title": "Department of HIV & AIDS and Viral Hepatitis", | 66 | "title": "Department of HIV & AIDS and Viral Hepatitis", | ||
57 | "type": "organization" | 67 | "type": "organization" | ||
58 | }, | 68 | }, | ||
59 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 69 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
60 | "private": false, | 70 | "private": false, | ||
61 | "program_area": "Care and Treatment", | 71 | "program_area": "Care and Treatment", | ||
62 | "relationships_as_object": [], | 72 | "relationships_as_object": [], | ||
63 | "relationships_as_subject": [], | 73 | "relationships_as_subject": [], | ||
64 | "resources": [ | 74 | "resources": [ | ||
65 | { | 75 | { | ||
66 | "cache_last_updated": null, | 76 | "cache_last_updated": null, | ||
67 | "cache_url": null, | 77 | "cache_url": null, | ||
68 | "created": "2023-07-13T19:59:09.463717", | 78 | "created": "2023-07-13T19:59:09.463717", | ||
69 | "description": "", | 79 | "description": "", | ||
70 | "format": "PDF", | 80 | "format": "PDF", | ||
71 | "hash": "", | 81 | "hash": "", | ||
72 | "id": "fb33adaa-95f9-42d1-b418-51db261e1449", | 82 | "id": "fb33adaa-95f9-42d1-b418-51db261e1449", | ||
73 | "last_modified": "2023-07-13T19:59:09.428725", | 83 | "last_modified": "2023-07-13T19:59:09.428725", | ||
74 | "lfs_prefix": | 84 | "lfs_prefix": | ||
75 | "dha/hiv-drug-resistance-testing-application-form-version2", | 85 | "dha/hiv-drug-resistance-testing-application-form-version2", | ||
76 | "metadata_modified": "2023-07-13T19:59:11.848180", | 86 | "metadata_modified": "2023-07-13T19:59:11.848180", | ||
77 | "mimetype": "application/pdf", | 87 | "mimetype": "application/pdf", | ||
78 | "mimetype_inner": null, | 88 | "mimetype_inner": null, | ||
79 | "name": "HIV drug resistance testing application form (version2, | 89 | "name": "HIV drug resistance testing application form (version2, | ||
80 | 2022)", | 90 | 2022)", | ||
81 | "package_id": "b29dd35e-fbfd-4f08-94ed-dfe0a222b911", | 91 | "package_id": "b29dd35e-fbfd-4f08-94ed-dfe0a222b911", | ||
82 | "position": 0, | 92 | "position": 0, | ||
83 | "resource_type": null, | 93 | "resource_type": null, | ||
84 | "sha256": | 94 | "sha256": | ||
85 | "2a98494d7cf6adc55657e8069018e3090bea10eb232dafe0f36bff53879d8071", | 95 | "2a98494d7cf6adc55657e8069018e3090bea10eb232dafe0f36bff53879d8071", | ||
86 | "size": 173904, | 96 | "size": 173904, | ||
87 | "state": "active", | 97 | "state": "active", | ||
88 | "url": | 98 | "url": | ||
89 | nload/hiv-drug-resistance-testing-application-form-version2-2022.pdf", | 99 | nload/hiv-drug-resistance-testing-application-form-version2-2022.pdf", | ||
90 | "url_type": "upload" | 100 | "url_type": "upload" | ||
91 | } | 101 | } | ||
92 | ], | 102 | ], | ||
93 | "state": "active", | 103 | "state": "active", | ||
94 | "tags": [ | 104 | "tags": [ | ||
95 | { | 105 | { | ||
96 | "display_name": "application form", | 106 | "display_name": "application form", | ||
97 | "id": "d1616958-4f82-48ca-aeb2-99ef30e5e620", | 107 | "id": "d1616958-4f82-48ca-aeb2-99ef30e5e620", | ||
98 | "name": "application form", | 108 | "name": "application form", | ||
99 | "state": "active", | 109 | "state": "active", | ||
100 | "vocabulary_id": null | 110 | "vocabulary_id": null | ||
101 | }, | 111 | }, | ||
102 | { | 112 | { | ||
103 | "display_name": "drug resistance", | 113 | "display_name": "drug resistance", | ||
104 | "id": "d11f3810-676d-4e35-811e-e0df464c2a96", | 114 | "id": "d11f3810-676d-4e35-811e-e0df464c2a96", | ||
105 | "name": "drug resistance", | 115 | "name": "drug resistance", | ||
106 | "state": "active", | 116 | "state": "active", | ||
107 | "vocabulary_id": null | 117 | "vocabulary_id": null | ||
108 | }, | 118 | }, | ||
109 | { | 119 | { | ||
t | t | 120 | "display_name": "featured", | ||
121 | "id": "22f37483-07b1-400c-a6e5-16ff1153a217", | ||||
122 | "name": "featured", | ||||
123 | "state": "active", | ||||
124 | "vocabulary_id": null | ||||
125 | }, | ||||
126 | { | ||||
110 | "display_name": "hiv", | 127 | "display_name": "hiv", | ||
111 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | 128 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | ||
112 | "name": "hiv", | 129 | "name": "hiv", | ||
113 | "state": "active", | 130 | "state": "active", | ||
114 | "vocabulary_id": null | 131 | "vocabulary_id": null | ||
115 | }, | 132 | }, | ||
116 | { | 133 | { | ||
117 | "display_name": "testing", | 134 | "display_name": "testing", | ||
118 | "id": "eadc59f0-fcde-422f-9aa2-2a863c0c6749", | 135 | "id": "eadc59f0-fcde-422f-9aa2-2a863c0c6749", | ||
119 | "name": "testing", | 136 | "name": "testing", | ||
120 | "state": "active", | 137 | "state": "active", | ||
121 | "vocabulary_id": null | 138 | "vocabulary_id": null | ||
122 | } | 139 | } | ||
123 | ], | 140 | ], | ||
124 | "title": "HIV drug resistance testing application form (version2, | 141 | "title": "HIV drug resistance testing application form (version2, | ||
125 | 2022)", | 142 | 2022)", | ||
126 | "type": "dataset", | 143 | "type": "dataset", | ||
127 | "url": null, | 144 | "url": null, | ||
128 | "version": null, | 145 | "version": null, | ||
129 | "year": "2022" | 146 | "year": "2022" | ||
130 | } | 147 | } |